RESEARCH ARTICLE

The Etiology, Incidence, and Impact of Preservation Fluid Contamination during Liver Transplantation

Isabel Oriol1*, Laura Lladó2, Marina Vila2, Carme Baliellas2, Fe Tubau3, Núria Sabé1, Joan Fabregat2, Jordi Carratalà1

1 Department of Infectious Diseases, Hospital de Bellvitge, Institut d’Investigació Biomèdica de Bellvitge, University of Barcelona, L’Hospitalet de Llobregat, Barcelona, Spain, 2 Liver Transplant Unit, Hospital de Bellvitge, Institut d’Investigació Biomèdica de Bellvitge, University of Barcelona, L’Hospitalet de Llobregat, Barcelona, Spain, 3 Department of Microbiology, Hospital de Bellvitge, Institut d’Investigació Biomèdica de Bellvitge, University of Barcelona, L’Hospitalet de Llobregat, Barcelona, Spain

* isaoriolbermudez@gmail.com

Abstract

The role of contaminated preservation fluid in the development of infection after liver transplantation has not been fully elucidated. To assess the incidence and etiology of contaminated preservation fluid and determine its impact on the subsequent development of infection after liver transplantation, we prospectively studied 50 consecutive liver transplants, and cultured the following samples in each instance: preservation fluid (immediately before and at the end of the back-table procedure, and just before implantation), blood, and bile from the donor, and ascitic fluid from the recipient. When any culture was positive, blood cultures were obtained and targeted antimicrobial therapy was started. We found that the incidence of contaminated preservation fluid was 92% (46 of 50 cases of liver transplantation per year), but only 28% (14/50) were contaminated by recognized pathogens. Blood and bile cultures from the donor were positive in 28% and 6% respectively, whereas ascitic fluid was positive in 22%. The most frequently isolated microorganisms were coagulase-negative staphylococci. In nine cases, the microorganisms isolated from the preservation fluid concurred with those grown from the donor blood cultures, and in one case, the isolate matched with the one obtained from bile culture. No liver transplant recipient developed an infection due to the transmission of an organism isolated from the preservation fluid. Our findings indicate that contamination of the preservation fluid is frequent in liver transplantation, and it is mainly caused by saprophytic skin flora. Transmission of infection is low, particularly among those recipients given targeted antimicrobial treatment for organisms isolated in the preservation fluid.

Introduction

Liver transplantation has become the definitive treatment of several end-stage liver diseases [1–3]. In recent years, with the growing disparity between organ availability and the number of candidates for liver transplantation, most centers have extended the acceptance criteria for
However, this strategy increases the risk of bacterial, viral, and fungal infections after transplantation [6,7], making post-transplant infection a leading cause of in-hospital mortality among liver transplant recipients [8–10].

Contamination of preservation fluid has been identified as a potential source of post-transplant infection [6,11], although the reported incidence ranges from as low as 9.5% to as high as 98.4% [7,12–14]. The frequency of infection transmitted via the preservation fluid varies depending on the type of the study [6,13]. Moreover, related case-fatality rates have been reported to exceed 50%, depending on the causative organisms [13]. However, our current understanding of the contamination of preservation fluid and subsequent recipient infection derives to a large extent from retrospective studies in which only a few fluids from patients were examined.

To detect allograft contamination and improve the early diagnosis and approach of infection-related complications, some transplant centers now routinely take intra-operative cultures of organ preservation fluid. However, evidence supporting this practice is scarce, and little is known about the most appropriate management strategy for liver recipients with confirmed preservation fluid contamination. In this study, we aimed to clarify the incidence and etiology of preservation fluid contamination in liver transplantation to determine the role of this contamination in the subsequent development of infection.

**Materials and Methods**

We conducted a prospective observational study at a tertiary university referral hospital for adults in Barcelona, Spain, where some 50 liver transplants are performed annually. For this study, we included all liver transplants from September 2012 to August 2013, collecting demographic and medical information from the donors and the recipients (including immunosuppressive treatment, occurrence of acute allograft rejection, infections, clinical features, microbiologic studies, and outcomes) as well as the operative data. All data were carefully recorded in a database. Differences in donor, baseline, and surgical characteristics of those undergoing liver transplantation were evaluated.

None of the transplant donors were from a vulnerable population and all donors or next of kin provided written informed consent that was freely given. Written informed consent was considered not necessary for the study, as it was an analysis of our usual everyday work. The data of the patients were anonymized for the purposes of this analysis. The confidential information of the patients was protected according national normative. This manuscript was approved for its publication by the Clinical Research Ethics Committee of Bellvitge University Hospital.

The microbiology reports for all the positive cultures (blood and preservation fluid) were reviewed daily by the infectious disease team, and patients were then followed up by an infectious disease physician. When pathogens were isolated from donor or preservation fluids, blood cultures were taken from the recipient and targeted antimicrobial therapy was prescribed. However, treatment was stopped if no clinical signs of infection developed or if cultures from the recipient were negative.

Grafts were routinely preserved in Celsior solution at 4°C. The liver was placed in a sterile plastic double-bag and transported in a third non-sterile bag. Back-table procedures were performed in a separate dedicated room near to where the organ retrieval was performed.

In order to detect the exact time when the PF is contaminated, and to understand which is the main mechanism involved in the contamination, three samples of preservation fluid were routinely obtained under sterile conditions (immediately before the back-table procedure, at the end of the back-table procedure, and just before implantation). Under sterile conditions,
we also systematically obtained blood and bile samples from donors and ascites samples from recipients.

Preservation fluid contamination during the back-table procedure was defined as isolation of any organism from the sample obtained after the back-table procedure, but not in the sample recovered before the back-table procedure. Contamination of the preservation fluid during liver transplantation was defined as isolation of any organism from the sample obtained just before the graft implantation, but not recovered from the sample obtained before the back-table procedure.

Infections were defined according to the CDC/NHSN guidelines [15]. In case of infection after liver transplantation, the source of infection was determined by clinical criteria and isolation of any organism from a clinically significant site of infection. When no sites were identified, infection was considered to be from a primary or unknown source.

Prior transplantation referred to re-transplantation of the same organ. Empirical antibiotic therapy was considered inadequate if the treatment regimen did not include at least one antibiotic with in vitro activity against the infecting microorganism. Shock was defined as a systolic blood pressure of less than 90 mmHg, which was unresponsive to fluid treatment or required vasoactive drug therapy [16]. Acute allograft rejection was diagnosed only when proven by biopsy. The overall case-fatality rate was defined as death by any cause within the first 30 days of the onset of infection.

All patients received perioperative antibacterial prophylaxis with teicoplanin plus aztreonam for up to 24 hours after transplantation. Antifungal prophylaxis was given to high-risk recipients according to current recommendations [17]. Prophylaxis against Pneumocystis jiroveci infection was with trimethoprim–sulfamethoxazole given as a single dose, three times a week, for the first 6 months after transplantation. Prophylaxis against cytomegalovirus (CMV) was given according to the current guidelines [18].

Samples were processed by the BACTEC 9240 method (Becton-Dickinson Microbiology Systems, Sparks, MD). The inoculated bottles were incubated for five days at 35°C before being discharged. Microbial identification was performed using commercially available panels (MicroScan [Siemens; West Sacramento, United States] or Vitek [Biomérieux; Marcy-L’Étoile, France]), by standard biochemical and/or enzymatic test, or by matrix-assisted laser desorption ionization (MALDI-TOF; Bruker Daltonik; Bremen, Germany). The Clinical and Laboratory Standards (CLSI) criteria were used to define susceptibility or resistance to antimicrobial agents. Antibiotic susceptibility was tested using the micro-dilution method, following CLSI guidelines [19].

The microbiologic results of the preservation fluid culture were compared to the results of samples from the donor and the recipient. The criteria for microorganism matching were based on species identification and susceptibility profiles.

The statistical analysis was performed using PASW Statistics for Windows, Version 18.0 (SPSS, Inc., Chicago, IL, USA). Categorical variables were characterized by percentages and compared with chi-square tests, while continuous variables were expressed as means and standard deviations, or as medians and interquartile ranges (IQR), according to their distribution. Comparisons were made using the Mann-Whitney U test. All statistical tests were two-tailed and the threshold of statistical significance was <0.05.

Results

We recorded the details of 50 consecutive liver transplantation among 47 patients during the study period. Table 1 shows the baseline characteristics for the liver donors and liver recipients, including the operation-related data. The median age of liver recipients was 57 (IQR 52–62) years, and 82% were male. The most frequent indication for liver transplantation was
hepatocellular carcinoma, followed by chronic hepatitis C and alcoholic cirrhosis. The median age of donors was 63 (IQR 51–69) years, and 64% were male. Two were domino transplants, but the remaining forty-eight were deceased-donor transplants. Causes of death of donors were stroke (35), head trauma (8), cerebral anoxia (4), and other (1). The median time of ischemia was 377 (IQR 310–480) minutes, and the median time of surgery was 385 (IQR 344–450) minutes.

The microorganisms isolated are detailed in full in Table 2. All cultures of the preservation fluids collected before the back-table procedure were negative. One or more microorganisms were isolated in the preservation fluids collected just before implantation in 46 out of 50 transplants, representing an incidence rate of 92% for contamination of the preservation fluid. In eight cases the contamination was polymicrobial, and in 14 cases (28%) the isolates were considered pathogens. Blood samples and bile samples were positive in 14 (28%) and three donors (6%) respectively, and ascites samples were positive in 11 out of 50 recipients (22%); but only two isolates were considered pathogens in each setting. In nine cases, isolates from the preservation fluid were consistent with those isolated in blood cultures from the donor; these were coagulase-negative staphylococci in seven cases, and streptococci viridans and candida spp. in one case each. In another case, the preservation fluid isolate (Enterobacter spp.) matched that obtained from the bile culture. S1 File links information about each recipient and their donor, as well as the operative features characteristics and the microorganisms isolated in each case.

Table 3 shows data of liver recipients with contaminated preservation fluid before implantation regarding microorganisms involved, susceptibility to antibiotic prophylaxis, treatment and

### Table 1. Baseline liver donor and recipient characteristics, and operation features characteristics.

| CHARACTERISTICS             | N = 50 |
|-----------------------------|--------|
| **Donor features**          |        |
| Age, median (IQR)           | 63 (51–69) |
| Weight (Kg), median (IQR)   | 80 (72–90) |
| Height (m), median (IQR)    | 1.7 (1.65–1.8) |
| Male sex, no. (%)           | 32 (64) |
| Heart disease, no. (%)      | 13 (26) |
| Length of ICU stay, median (IQR) | 2 (1–6) |
| **Operative features**      |        |
| Cold ischemia time (minutes), median (IQR) | 377 (310–480) |
| Length of surgery (minutes), median (IQR) | 385 (344–450) |
| Red blood cell transfusion, no. (%) | 29 (58) |
| Fresh-frozen plasma transfusion, no. (%) | 15 (30) |
| Platelets transfusion, no. (%) | 27 (54) |
| **Recipient features**      |        |
| Age, median (IQR)           | 57 (52–62) |
| Male sex, no. (%)           | 41 (82) |
| HTA pre-LT, no. (%)         | 13 (26) |
| DM pre-LT, no. (%)          | 9 (18) |
| MELD, median (IQR)          | 20 (15–25) |
| Length of ICU stay post-LT (days), median (IQR) | 3 (2–4) |
| Length of hospitalization post-LT (days), median (IQR) | 12 (9–20) |
| Infection during the first month post-LT, no. (%) | 6 (12) |
| Overall case-fatality rate, no. (%) | 1 (2) |

IQR: Interquartile range; ICU: Intensive Care Unit; HTA: arterial hypertension; DM: Diabetes mellitus; LT: liver transplantation; MELD: Model of End-Stage Liver Disease

doi:10.1371/journal.pone.0160701.t001

Contaminated Preservation Fluid on Liver Transplantation

PLOS ONE | DOI:10.1371/journal.pone.0160701 August 11, 2016
outcomes. The median duration of targeted antibiotic treatment, for those liver recipients with contaminated preservation fluid, was 6 (IQR 4.8–7.5) days.

During the study period, only six recipients suffered infections during the first month after liver transplantation, although none of these was due to possible pathogen transmission from the donor to the recipient. Three recipients required re-transplantation for ischemic cholangitis, acute cellular graft rejection, and hepatic artery thrombosis. One recipient died because of an acute hepatic artery thrombosis.

Finally, we compared various donor and surgical features as well as the outcomes between liver recipients with and without the growth of pathogens in the preservation fluid culture collected just before implantation. Table 4 summarizes the results of the between-group comparison. No statistical differences were found.

**Discussion**

In this prospective study of 50 consecutive liver transplants, the incidence of preservation fluid contamination was 92% just before implantation. True pathogenic contamination accounted for 28%. Despite this high incidence, however, we did not identify any cases of infectious transmission.

Previous studies have reported a wide variability in the incidence of preservation fluid contamination [7,12–14], which may be due to the fact that some reports define contamination as the positive growth of any microorganism, while others require the isolation of known human pathogens [20,21]. In addition, the time of collection of samples during the process of liver transplantation, and the sensitivity of culture methods, differ among the published studies [6,22]. At present, little is known about the clinical value of collecting and culturing the preservation fluid, or about the appropriate management of recipients with positive cultures from preservation fluid samples.
Given that the prevalence of preservation fluid contamination was high, it is reasonable to speculate that the lack of infection transmission is related to the use of early, targeted antimicrobial treatment. However, we identified matches between isolates in the preservation fluid and isolates in the blood and bile cultures of donors, suggesting that this is a plausible route of infection transmission. It should be noted, however, that we did not perform a molecular epidemiology analysis, which would be necessary to confirm that these were truly the same microorganisms.

Few reports in the literature have shown the transmission of infection from donor to recipient through preservation fluid contamination [6,13,23,24]. When reported, the mortality rate in cases of infectious transmission is high [13,25]. Moreover, the scarce literature available suggests that transmission via the contamination of the preservation fluid is always related to known human pathogens. In the absence of data to the contrary, we should probably consider recipients at risk if these pathogens grow in preservation fluid cultures.

We collected preservation fluid samples at different times during the transplant procedure in an attempt to detect when preservation fluid was contaminated. In this regard, our findings concurred with those found by previous researchers who suggested that preservation fluid is most frequently contaminated during harvesting and manipulation in the back-table procedure [7]. Indeed, in the present study, all preservation fluid cultures before the back-table procedure were negative, while 92% of that collected just before implantation grew microorganisms.

Table 3. Liver recipients with contaminated preservation fluid before implantation: microorganisms involved, susceptibility to antimicrobial prophylaxis, treatment and outcomes.

| Case | Organisms isolated in the PF | AAP | AP | Treatment | Days of treatment | Length of ICU stay (days) | LOS (days) | Infection\(^1\) | Re-transplantation | Death |
|------|-----------------------------|-----|----|-----------|-------------------|--------------------------|-----------|----------------|------------------|-------|
| 1    | Serratia spp                | Yes | Yes| Ertapenem | 4                 | 3                        | 9         | No             | No               | No    |
| 2    | Enterococcus faecalis       | Yes | Yes| Meropenem | 6                 | 2                        | 26        | Cholangitis and E. faecium bacteremia | No               |       |
| 3    | Enterococcus faecium        | Yes | Yes| Linezolid | 15                | 2                        | 12        | No             | No               | No    |
| 4    | Enterobacter cloacae        | No  | No | Ciprofloxacin | 4                | 3                        | 8         | No             | No               | No    |
| 5    | Staphylococcus aureus       | Yes | No | Ceftazolin | 6                 | 3                        | 19        | No             | No               | No    |
| 6    | Enterobacter cloacae        | No  | No | Amoxicillin + Ciprofloxacin | 7                | 3                        | 12        | No             | No               | No    |
| 7    | Staphylococcus aureus       | Yes | No | Teicoplanin/ Daptomycin | 6                | 2                        | 12        | No             | No               | No    |
| 8    | Staphylococcus aureus       | Yes | No | Aztreonam + Teicoplanin | 5                | 4                        | 12        | No             | No               | No    |
| 9    | Enterobacter aerogenes      | Yes | No | Ertapenem | 10                | 8                        | 34        | No             | No               | No    |
| 10   | Staphylococcus aureus       | Yes | No | Linezolid | 9                 | 10                       | 23        | No             | No               | No    |
| 11   | Streptococcus pneumoniae    | Yes | No | Ceftriaxone | 4                | 2                        | 7         | No             | No               | No    |
| 12   | Staphylococcus aureus       | Yes | No | Daptomycin | 5                 | 2                        | 8         | No             | No               | No    |
| 13   | Escherichia coli            | Yes | Yes| Ceftriaxone | 7                | 10                       | 37        | No             | No               | No    |
| 14   | Candida glabrata CNS        | No  | No | Anidulafungin | 7                | 2                        | 10        | No             | No               | No    |

Abbreviations: AAP, adequate antibiotic prophylaxis; AP, antifungal prophylaxis; CNS, Coagulase-negative staphylococci; ICU, Intensive Care Unit; LOS, Length of hospitalization post-LT; N, no; PF, preservation fluid; Y, yes

\(^1\) Infection during the first month post-LT

doi:10.1371/journal.pone.0160701.t003
Moreover, the most frequently isolated microorganisms were superficial saprophytic flora, which could have occurred at any of a number of stages during the transplantation process, including the multiple-step procedures and the packaging of the liver after removal from the donor. Our data indicate that the most appropriate time to culture preservation fluids would be just before implantation and that taking other samples is probably of limited clinical value.

Among the strengths of this study are the prospective design and that we included a large number of different samples collected at different points during the transplant process, finding that contamination varies according to the time of samples. However, it should be acknowledged that our study has some limitations. For example, this was a single center study; in addition, due to the small size of our series, it was not possible to compare the differences between positive and negative cultures to identify risk factors for preservation fluid contamination.

**Conclusions**

Preservation fluid contamination is frequent during liver transplantation, and it is mainly caused by superficial saprophytic flora. Transmission of infection is low among those recipients given targeted antimicrobial treatment for organisms isolated in the preservation fluid. However, prospective multicenter studies, which should include molecular epidemiological analyses, are required to determine the optimal strategies for the prevention and management of subsequent infection.

**Supporting Information**

S1 File. Liver donor and recipient characteristics, operation features characteristics and microorganisms isolated in blood, bile, ascites and preservation fluid cultures.

**Author Contributions**

Conceived and designed the experiments: IO LL MV CB NS JF JC.
Performed the experiments: IO LL MV CB FT NS JF JC.

Analyzed the data: IO NS JC.

Contributed reagents/materials/analysis tools: FT.

Wrote the paper: IO LL NS JC.

References

1. Lucey MR. Liver transplantation in patients with alcoholic liver disease. Liver Transpl. 2011 Jul; 17 (7):751–9. doi: 10.1002/lt.22330 PMID: 21567894

2. Khullar V, Firpi RJ. Hepatitis C cirrhosis: New perspectives for diagnosis and treatment. World J Hepatol. 2015 Jul 18; 7(4):1843–55. doi: 10.4254/wjh.v7.i4.1843 PMID: 26207166

3. Liberal R, Zen Y, Mieli-Vergani G, Vergani D. Liver transplantation and autoimmune liver diseases. Liver Transpl. 2013 Oct; 19(10):1065–77. doi: 10.1002/lt.23704 PMID: 23873751

4. Len O, Gavaldá J, Blanes M, Montejo M, San Juan R, Moreno A, et al. Donor infection and transmission to the recipient of a solid allograft. Am J Transplant. 2008 Nov; 8(11):2420–5. doi: 10.1111/j.1600-6143.2008.02397.x PMID: 18925908

5. Gavaldà J, Blanes M, Montejo M, San Juan R, Moreno A, et al. Use of extended criteria livers decreases wait time for liver transplantation without adversely impacting posttransplant survival. Ann Surg. 2006 Sep; 244(3):439–50. PMID: 16926570

6. Cerutti E, Stratta C, Romagnoli R, Serra R, Lepore M, Fop F, et al. Bacterial- and fungal-positive cultures in organ donors: clinical impact in liver transplantation. Liver Transpl. 2006 Aug; 12(8):1253–9. PMID: 16724336

7. Gavaldà J, Meije Y, Fortun J, Rolídes E, Sañé F, Lortholary O, et al. Invasive fungal infections in solid organ transplant recipients. Clin Microbiol Infect. 2014 Sep 9; 20(10):1929–37. doi: 10.1111/cmi.12737 PMID: 24961423

8. Dorschner P, McElroy LM, Ison MG. Nosocomial infections within the first month of solid organ transplantation. Transpl Infect Dis. 2014 Apr; 16(2):171–87. doi: 10.1111/tid.12309 PMID: 24661423

9. Avkan-Oguz V, Ozkardesler S, Unek T, Ozbilgin M, Akan M, Firuzan E, et al. Risk factors for early bacterial infections in liver transplantation. Transplant Proc. 2013 Apr; 45(3):993–7. doi: 10.1016/j.transproceed.2013.02.067 PMID: 23622606

10. Gavaldà J, Aguado JM, Manuel O, Grossi P, Hirsch HH. A special issue on infections in solid organ transplant recipients. Clin Microbiol Infect. 2014 Sep; 20 Suppl 7:1–3. doi: 10.1111/1469-0691.12658 PMID: 24809974

11. Fishman JA. From the classic concepts to modern practice. Clin Microbiol Infect. 2014 Sep; 20 Suppl 7:4–9. doi: 10.1111/1469-0691.12593 PMID: 24528498

12. Chaim FHM, Boin IFSF, Ataide EC, Stucchi RSB. Perfusion fluid contamination in relation to recipient survival and acute cellular rejection in orthotopic liver transplantation: retrospective analysis. Transplant Proc. 2011 May; 43(4):1313–5. doi: 10.1016/j.transproceed.2011.02.030 PMID: 21820118

13. Janny S, Bert F, Dondero F, Durand F, Guerini P, Merckx P, et al. Microbiological findings of culture-positive preservation fluid in liver transplantation. Transpl Infect Dis. 2011 Feb; 13(1):9–14. doi: 10.1111/j.1399-3062.2010.00558.x PMID: 20738832

14. Ruiz P, Gastaca M, Gonzalez J, Hernandez MJ, Ventoso A, Valdivieso A, et al. Incidence and clinical relevance of bacterial contamination in preservation solution for liver transplantation. Transplant Proc. 2011 May; 43(3):1080–2. doi: 10.1016/j.transproceed.2011.02.067 PMID: 21820252

15. Chaim FHM, Boin IFSF, Ataide EC, Stucchi RSB. Perfusion fluid contamination in relation to recipient survival and acute cellular rejection in orthotopic liver transplantation: retrospective analysis. Transplant Proc. 2011 May; 43(4):1313–5. doi: 10.1016/j.transproceed.2011.02.030 PMID: 21820118

16. Janny S, Bert F, Dondero F, Durand F, Guerini P, Merckx P, et al. Microbiological findings of culture-positive preservation fluid in liver transplantation. Transpl Infect Dis. 2011 Feb; 13(1):9–14. doi: 10.1111/j.1399-3062.2010.00558.x PMID: 20738832

17. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008 Jun; 36(5):309–32. doi: 10.1016/j.ajic.2008.03.002 PMID: 18538699

18. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013 Feb; 41(2):680–687. doi: 10.1097/CCM.0b013e318278f3a PMID: 23353941

19. Gavaldà J, Meije Y, Fortun J, Rolídes E, Sañé F, Lortholary O, et al. Invasive fungal infections in solid organ transplant recipients. Clin Microbiol Infect. 2014 Sep; 20 Suppl 7:27–48. doi: 10.1111/1469-0691.12660 PMID: 24810152

20. Lumbreras C, Manuel O, Len O, ten Berge JM, Sgarabotto D, Hirsch HH. Cytomegalovirus infection in solid organ transplant recipients. Clin Microbiol Infect. 2014 Sep 9; 20:19–26.
19. Wayne P. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing: Twenty-second informational supplement M100-S22 USA. 2012.

20. Mattana AMC, Marra AR, Machado AM, Lopes Filho G de J, Salzedas Netto AA, Gonzalez AM. Evaluation of the presence of microorganisms in solid-organ preservation solution. Braz J Infect Dis. Jan; 15(6):528–32. PMID: 22218510

21. Yansouni CP, Dendukuri N, Liu G, Fernandez M, Frenette C, Paraskevas S, et al. Positive cultures of organ preservation fluid predict postoperative infections in solid organ transplantation recipients. Infect Control Hosp Epidemiol. 2012 Jul; 33(7):672–80. doi: 10.1086/666344 PMID: 22669228

22. Veroux M, Corona D, Scriffignano V, Caglià P, Gagliano M, Giuffrida G, et al. Contamination of preservation fluid in kidney transplantation: single-center analysis. Transplant Proc. 2010 May; 42(4):1043–5. doi: 10.1016/j.transproceed.2010.03.041 PMID: 20534219

23. Sauget M, Verdy S, Slekovc E, Bertrand X, Talon D. Bacterial contamination of organ graft preservation solution and infection after transplantation. Transpl Infect Dis. 2011 Aug; 13(4):331–4. doi: 10.1111/j.1399-3062.2010.00597.x PMID: 21281417

24. Audet M, Piardi T, Panaro F, Ghislotti E, Gheza F, Cag M, et al. Incidence and clinical significance of bacterial and fungal contamination of the preservation solution in liver transplantation. Transpl Infect Dis. 2011 Feb; 13(1):84–8. doi: 10.1111/j.1399-3062.2010.00529.x PMID: 20576020

25. Levesque E, Suet G, Merle JC, Compagnon P, Amathieu R, Feray C, et al. Candida vascular complication in a liver transplant recipient due to yeast contamination of preservation solution. Transpl Infect Dis. 2014 Oct; 16(5):827–9. doi: 10.1111/tid.12260 PMID: 24981194